Navigation Links
Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2009 Financial Results
Date:5/5/2009

SCOTTSDALE, Ariz., May 5 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets products that provide consumers with "Better Ways to Get Better(R)," announced today that its financial results for the fiscal fourth quarter and year ended March 31, 2009, will be released after the market closes on Monday, May 11, 2009. An earnings conference call will be held the following morning on Tuesday, May 12, 2009 at 11:00 AM ET.

To access the teleconference, please call (877) 795-3610 (domestic) or (719) 325-4791 (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations.

A replay of the call will be available at (888) 203-1112 (domestic) or (719) 457-0820 (international), replay code 5362814 for 3 days following the call, and the web cast will be archived on the company's website, http://www.matrixxinc.com, for 30 days.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam(R) products in the cough and cold category. Zicam Canada, Inc., a wholly-owned subsidiary of Zicam, LLC markets and sells select Zicam products in Canada. The Company's flagship product, Zicam Cold Remedy nasal gel, is a patented, homeopathic remedy that has been clinically proven to reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT -- Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce the duration of the common cold. The Company also manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy Swabs(TM); Zicam Cold Remedy Chewables(TM); Zicam Cold Remedy Oral Mist(TM); Zicam Cold Remedy RapidMelts(TM); Zicam Allergy Relief; Zicam Extreme Congestion Relief; Zicam Sinus Relief; as well as Zicam Cough products and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, Acting President and Chief Operating Officer, 602-385-8888, or Bill Barba, Treasurer & Investor Relations, at 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.


'/>"/>
SOURCE Matrixx Initiatives, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share
3. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2009 Financial Results
4. Matrixx Initiatives Selects GolinHarris as Agency of Record for Zicam Brand
5. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
6. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
7. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
10. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
11. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... The National Campaign to Prevent Teen ... to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, introduced ... to ensure that all members of the Armed Forces receive high quality education ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... or hERG liability could substantially improve drug safety and minimize the cost of ... for validating ion channel inhibition using cell lines and for cardiac toxicity using ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... for the North East region. Côté has 20+ years of experience within the ... Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
Breaking Medicine Technology: